| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 Oxford University Press
ARTICLE |
MGMT Promoter Methylation and Field Defect in Sporadic Colorectal Cancer
Affiliations of authors: Departments of Leukemia (LS, YK, NSH, JV, J-PJI), Biostatistics and Applied Biomathematics (GLR, LX), and Pathology (PSH, SRH), The University of Texas at M. D. Anderson Cancer Center, Houston, TX; Departments of Surgery (RSK) and Pathology (ARP), University of Arizona, Tucson, AZ, and Southern Arizona Veterans Affairs Health Care System, Tucson, AZ; Arizona Cancer Center (JGE, JB, DSA), University of Arizona, Tucson, AZ
Correspondence to: Jean-Pierre Issa, MD, Department of Leukemia, M. D. Anderson Cancer Center, Unit 428, 1515 Holcombe Blvd., Houston, TX 77030 (e-mail: jpissa{at}mdanderson.org).
Background: Sporadic colorectal cancers often arise from a region of cells characterized by a "field defect" that has not been well defined molecularly. DNA methylation has been proposed as a candidate mediator of this field defect. The DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) is frequently methylated in colorectal cancer. We hypothesized that MGMT methylation could be one of the mediators of field cancerization in the colon mucosa. Methods: We studied MGMT promoter methylation by three different bisulfite-based techniques in tumor, adjacent mucosa, and nonadjacent mucosa from 95 colorectal cancer patients and in colon mucosa from 33 subjects with no evidence of cancer. Statistical tests were two-sided. Results: MGMT promoter methylation was present in 46% of the tumors. Patients whose cancer had MGMT promoter methylation also had substantial MGMT promoter methylation in apparently normal adjacent mucosa. This methylation was seen with a quantitative assay in 50% (22/44; 95% confidence interval [CI] = 34% to 65%) of normal samples with MGMT promoter methylation in the adjacent tumors, 6% (3/51; 95% CI = 1% to 16%) of samples without MGMT methylation in adjacent tumors, and 12% (4/33; 95% CI = 3% to 28%) of control samples (P<.001 for comparison between each of the latter two groups and the first group). MGMT methylation was detected with a more sensitive assay in 94%, 34%, and 27% of these samples, respectively (P<.001). In grossly normal colonic mucosa of colon cancer patients, methylation was detected 10 cm away from the tumor in 10 of 13 cases. Tumors with MGMT promoter methylation had a higher rate of G-to-A mutation in the KRAS oncogene than tumors without MGMT promoter methylation (10/42 versus 3/46, P = .03). Using a sensitive mutant allele-specific amplification assay for KRAS mutations, we also found KRAS mutations in 12% (3/25; 95% CI = 2.5% to 31%) of colorectal mucosas with detectable MGMT methylation and 3% (2/64; 95% CI = 0.4% to 11%) of colorectal mucosas without MGMT methylation (P = .13). Conclusion: Some colorectal cancers arise from a field defect defined by epigenetic inactivation of MGMT. Detection of this abnormality may ultimately be useful in risk assessment for colorectal cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
Editorial about this Article
- DNA Methylation, Field Effects, and Colorectal Cancer
- Edward Giovannucci and Shuji Ogino
J Natl Cancer Inst 2005 97: 1317-1319.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  I. L.M. Candiloro and A. Dobrovic Detection of MGMT Promoter Methylation in Normal Individuals Is Strongly Associated with the T Allele of the rs16906252 MGMT Promoter Single Nucleotide Polymorphism Cancer Prevention Research, October 1, 2009; 2(10): 862 - 867. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Hitchins and R. L. Ward Favoritism in DNA Methylation Cancer Prevention Research, October 1, 2009; 2(10): 847 - 849. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. B. Lee, E. J. Lee, E. H. Jung, H.-K. Chun, D. K. Chang, S. Y. Song, J. Park, and D.-H. Kim Aberrant Methylation of APC, MGMT, RASSF2A, and Wif-1 Genes in Plasma as a Biomarker for Early Detection of Colorectal Cancer Clin. Cancer Res., October 1, 2009; 15(19): 6185 - 6191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nagasaka, N. Tanaka, H. M. Cullings, D.-S. Sun, H. Sasamoto, T. Uchida, M. Koi, N. Nishida, Y. Naomoto, C. R. Boland, et al. Analysis of Fecal DNA Methylation to Detect Gastrointestinal Neoplasia J Natl Cancer Inst, September 16, 2009; 101(18): 1244 - 1258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L Worthley, R. K Le Leu, V. L Whitehall, M. Conlon, C. Christophersen, D. Belobrajdic, K.-A. Mallitt, Y. Hu, N. Irahara, S. Ogino, et al. A human, double-blind, placebo-controlled, crossover trial of prebiotic, probiotic, and synbiotic supplementation: effects on luminal, inflammatory, epigenetic, and epithelial biomarkers of colorectal cancer Am. J. Clinical Nutrition, September 1, 2009; 90(3): 578 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Concordant DNA Methylation in Synchronous Colorectal Carcinomas Cancer Prevention Research, September 1, 2009; 2(9): 814 - 822.
|
|
|
|
 |
|
 S. de Vogel, M. P. Weijenberg, J. G. Herman, K. A. D. Wouters, A. F. P. M. de Goeij, P. A. van den Brandt, A. P. de Bruine, and M. van Engeland MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events Ann. Onc., July 1, 2009; 20(7): 1216 - 1222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M.E.I. Hellebrekers, M. H.F.M. Lentjes, S. M. van den Bosch, V. Melotte, K. A.D. Wouters, K. L.J. Daenen, K. M. Smits, Y. Akiyama, Y. Yuasa, S. Sanduleanu, et al. GATA4 and GATA5 are Potential Tumor Suppressors and Biomarkers in Colorectal Cancer Clin. Cancer Res., June 15, 2009; 15(12): 3990 - 3997. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Rhiner and E. Moreno Super competition as a possible mechanism to pioneer precancerous fields Carcinogenesis, May 1, 2009; 30(5): 723 - 728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Balic, M. Pichler, J. Strutz, E. Heitzer, C. Ausch, H. Samonigg, R. J. Cote, and N. Dandachi High Quality Assessment of DNA Methylation in Archival Tissues from Colorectal Cancer Patients Using Quantitative High-Resolution Melting Analysis J. Mol. Diagn., March 1, 2009; 11(2): 102 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Deng, S. Kakar, K. Okudiara, E. Choi, M. H. Sleisenger, and Y. S. Kim Unique Methylation Pattern of Oncostatin M Receptor Gene in Cancers of Colorectum and Other Digestive Organs Clin. Cancer Res., March 1, 2009; 15(5): 1519 - 1526. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Chai and R. E. Brown Field Effect in Cancer-An Update Ann. Clin. Lab. Sci., January 1, 2009; 39(4): 331 - 337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. H. Gort, K. P.M. Suijkerbuijk, S. M. Roothaan, V. Raman, M. Vooijs, E. van der Wall, and P. J. van Diest Methylation of the TWIST1 Promoter, TWIST1 mRNA Levels, and Immunohistochemical Expression of TWIST1 in Breast Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2008; 17(12): 3325 - 3330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Milicic, L.-A. Harrison, R. A. Goodlad, R. G. Hardy, A. M. Nicholson, M. Presz, O. Sieber, S. Santander, J. H. Pringle, N. Mandir, et al. Ectopic Expression of P-Cadherin Correlates with Promoter Hypomethylation Early in Colorectal Carcinogenesis and Enhanced Intestinal Crypt Fission In vivo Cancer Res., October 1, 2008; 68(19): 7760 - 7768. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Hegi, L. Liu, J. G. Herman, R. Stupp, W. Wick, M. Weller, M. P. Mehta, and M. R. Gilbert Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity J. Clin. Oncol., September 1, 2008; 26(25): 4189 - 4199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-P. Issa Cancer Prevention: Epigenetics Steps Up to the Plate Cancer Prevention Research, September 1, 2008; 1(4): 219 - 222. [Full Text] [PDF]
|
|
|
|
|
|
Y. Suehiro, C. W. Wong, L. R. Chirieac, Y. Kondo, L. Shen, C. R. Webb, Y. W. Chan, A. S.Y. Chan, T. L. Chan, T.-T. Wu, et al. Epigenetic-Genetic Interactions in the APC/WNT, RAS/RAF, and P53 Pathways in Colorectal Carcinoma Clin. Cancer Res., May 1, 2008; 14(9): 2560 - 2569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Shen, Y. Kondo, S. Ahmed, Y. Boumber, K. Konishi, Y. Guo, X. Chen, J. N. Vilaythong, and J.-P. J. Issa Drug Sensitivity Prediction by CpG Island Methylation Profile in the NCI-60 Cancer Cell Line Panel Cancer Res., December 1, 2007; 67(23): 11335 - 11343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Shen, M. Toyota, Y. Kondo, E Lin, L. Zhang, Y. Guo, N. S. Hernandez, X. Chen, S. Ahmed, K. Konishi, et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer PNAS, November 20, 2007; 104(47): 18654 - 18659. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. M Grady CIMP and colon cancer gets more complicated Gut, November 1, 2007; 56(11): 1498 - 1500. [Full Text] [PDF]
|
|
|
|
|
|
S. Ogino, T. Kawasaki, G. J Kirkner, Y. Suemoto, J. A Meyerhardt, and C. S Fuchs Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer Gut, November 1, 2007; 56(11): 1564 - 1571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ogino, A. Hazra, G. J. Tranah, G. J. Kirkner, T. Kawasaki, K. Nosho, M. Ohnishi, Y. Suemoto, J. A. Meyerhardt, D. J. Hunter, et al. MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer Carcinogenesis, September 1, 2007; 28(9): 1985 - 1990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Nosho, H. Yamamoto, T. Takahashi, M. Mikami, H. Taniguchi, N. Miyamoto, Y. Adachi, Y. Arimura, F. Itoh, K. Imai, et al. Genetic and epigenetic profiling in early colorectal tumors and prediction of invasive potential in pT1 (early invasive) colorectal cancers Carcinogenesis, June 1, 2007; 28(6): 1364 - 1370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. M Grady and C. M Ulrich DNA alkylation and DNA methylation: cooperating mechanisms driving the formation of colorectal adenomas and adenocarcinomas? Gut, March 1, 2007; 56(3): 318 - 320. [Full Text] [PDF]
|
|
|
|
|
|
J J L Wong, N J Hawkins, and R L Ward Colorectal cancer: a model for epigenetic tumorigenesis Gut, January 1, 2007; 56(1): 140 - 148. [Full Text] [PDF]
|
|
|
|
|
|
P. S. Yan, C. Venkataramu, A. Ibrahim, J. C. Liu, R. Z. Shen, N. M. Diaz, B. Centeno, F. Weber, Y.-W. Leu, C. L. Shapiro, et al. Mapping Geographic Zones of Cancer Risk with Epigenetic Biomarkers in Normal Breast Tissue. Clin. Cancer Res., November 15, 2006; 12(22): 6626 - 6636. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Young and J. R. Jass The case for a genetic predisposition to serrated neoplasia in the colorectum: hypothesis and review of the literature. Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 1778 - 1784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P Minoo, K Baker, R Goswami, G Chong, W D Foulkes, A R Ruszkiewicz, M Barker, D Buchanan, J Young, and J R Jass Extensive DNA methylation in normal colorectal mucosa in hyperplastic polyposis Gut, October 1, 2006; 55(10): 1467 - 1474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Einspahr, M. E. Martinez, R. Jiang, C.-H. Hsu, A. K. Bhattacharrya, D. J. Ahnen, E. T. Jacobs, P. S. Houlihan, C. R. Webb, D. S. Alberts, et al. Associations of Ki-ras Proto-oncogene Mutation and p53 Gene Overexpression in Sporadic Colorectal Adenomas with Demographic and Clinicopathologic Characteristics. Cancer Epidemiol. Biomarkers Prev., August 1, 2006; 15(8): 1443 - 1450. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Guo, J. Ren, M. G. House, Y. Qi, M. V. Brock, and J. G. Herman Accumulation of Promoter Methylation Suggests Epigenetic Progression in Squamous Cell Carcinoma of the Esophagus Clin. Cancer Res., August 1, 2006; 12(15): 4515 - 4522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Ogino, M Cantor, T Kawasaki, M Brahmandam, G J Kirkner, D J Weisenberger, M Campan, P W Laird, M Loda, and C S Fuchs CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies Gut, July 1, 2006; 55(7): 1000 - 1006. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Greenspan, M. A. Jablonski, T. V. Rajan, J. Levine, G. S. Belinsky, and D. W. Rosenberg Epigenetic alterations in RASSF1A in human aberrant crypt foci Carcinogenesis, July 1, 2006; 27(7): 1316 - 1322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Furlan, I. Carnevali, B. Marcomini, R. Cerutti, E. Dainese, C. Capella, and C. Riva The High Frequency of De novo Promoter Methylation in Synchronous Primary Endometrial and Ovarian Carcinomas. Clin. Cancer Res., June 1, 2006; 12(11): 3329 - 3336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ogino, T. Kawasaki, M. Brahmandam, M. Cantor, G. J. Kirkner, D. Spiegelman, G. M. Makrigiorgos, D. J. Weisenberger, P. W. Laird, M. Loda, et al. Precision and Performance Characteristics of Bisulfite Conversion and Real-Time PCR (MethyLight) for Quantitative DNA Methylation Analysis J. Mol. Diagn., May 1, 2006; 8(2): 209 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Umetani, M. F.G. de Maat, E. Sunami, S. Hiramatsu, S. Martinez, and D. S.B. Hoon Methylation of p16 and Ras Association Domain Family Protein 1a during Colorectal Malignant Transformation Mol. Cancer Res., May 1, 2006; 4(5): 303 - 309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Liu and S. L. Gerson Targeted Modulation of MGMT: Clinical Implications Clin. Cancer Res., January 15, 2006; 12(2): 328 - 331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Giovannucci and S. Ogino DNA Methylation, Field Effects, and Colorectal Cancer J Natl Cancer Inst, September 21, 2005; 97(18): 1317 - 1319. [Full Text] [PDF]
|
|